These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with Gennari A; Brain E; De Censi A; Nanni O; Wuerstlein R; Frassoldati A; Cortes J; Rossi V; Palleschi M; Alberini JL; Matteucci F; Piccardo A; Sacchetti G; Ilhan H; D'Avanzo F; Ruffilli B; Nardin S; Monti M; Puntoni M; Fontana V; Boni L; Harbeck N; Ann Oncol; 2024 Jun; 35(6):549-558. PubMed ID: 38423389 [TBL] [Abstract][Full Text] [Related]
4. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400 [TBL] [Abstract][Full Text] [Related]
5. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. Linden HM; Stekhova SA; Link JM; Gralow JR; Livingston RB; Ellis GK; Petra PH; Peterson LM; Schubert EK; Dunnwald LK; Krohn KA; Mankoff DA J Clin Oncol; 2006 Jun; 24(18):2793-9. PubMed ID: 16682724 [TBL] [Abstract][Full Text] [Related]
6. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo? Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040 [TBL] [Abstract][Full Text] [Related]
7. The Predictive Value of Early Changes in He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493 [TBL] [Abstract][Full Text] [Related]
8. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274 [TBL] [Abstract][Full Text] [Related]
9. Kumar M; Salem K; Michel C; Jeffery JJ; Yan Y; Fowler AM J Nucl Med; 2019 Sep; 60(9):1247-1252. PubMed ID: 30850489 [TBL] [Abstract][Full Text] [Related]
10. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT. Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191 [TBL] [Abstract][Full Text] [Related]
11. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. Kurland BF; Peterson LM; Lee JH; Linden HM; Schubert EK; Dunnwald LK; Link JM; Krohn KA; Mankoff DA J Nucl Med; 2011 Oct; 52(10):1541-9. PubMed ID: 21903739 [TBL] [Abstract][Full Text] [Related]
12. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Linden HM; Kurland BF; Peterson LM; Schubert EK; Gralow JR; Specht JM; Ellis GK; Lawton TJ; Livingston RB; Petra PH; Link JM; Krohn KA; Mankoff DA Clin Cancer Res; 2011 Jul; 17(14):4799-805. PubMed ID: 21750198 [TBL] [Abstract][Full Text] [Related]
13. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. Peterson LM; Mankoff DA; Lawton T; Yagle K; Schubert EK; Stekhova S; Gown A; Link JM; Tewson T; Krohn KA J Nucl Med; 2008 Mar; 49(3):367-74. PubMed ID: 18287268 [TBL] [Abstract][Full Text] [Related]
14. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[ Katzenellenbogen JA Nucl Med Biol; 2021 Jan; 92():24-37. PubMed ID: 32229068 [TBL] [Abstract][Full Text] [Related]
15. A Randomized Feasibility Study of Chae SY; Kim SB; Ahn SH; Kim HO; Yoon DH; Ahn JH; Jung KH; Han S; Oh SJ; Lee SJ; Kim HJ; Son BH; Gong G; Lee HS; Moon DH J Nucl Med; 2017 Apr; 58(4):563-568. PubMed ID: 27688475 [TBL] [Abstract][Full Text] [Related]
16. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364 [TBL] [Abstract][Full Text] [Related]
17. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications. Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053 [TBL] [Abstract][Full Text] [Related]
18. Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657 [TBL] [Abstract][Full Text] [Related]
19. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Dehdashti F; Flanagan FL; Mortimer JE; Katzenellenbogen JA; Welch MJ; Siegel BA Eur J Nucl Med; 1999 Jan; 26(1):51-6. PubMed ID: 9933662 [TBL] [Abstract][Full Text] [Related]
20. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies. Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]